Browse F10

Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00008 EGF-like domain
PF00594 Vitamin K-dependent carboxylation/gamma-carboxyglutamic (GLA) domain
PF00089 Trypsin
Function

Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.

> Gene Ontology
 
Biological Process GO:0006465 signal peptide processing
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0007596 blood coagulation
GO:0007597 blood coagulation, intrinsic pathway
GO:0007598 blood coagulation, extrinsic pathway
GO:0007599 hemostasis
GO:0016485 protein processing
GO:0017187 peptidyl-glutamic acid carboxylation
GO:0018200 peptidyl-glutamic acid modification
GO:0018214 protein carboxylation
GO:0030335 positive regulation of cell migration
GO:0040017 positive regulation of locomotion
GO:0043491 protein kinase B signaling
GO:0048193 Golgi vesicle transport
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051272 positive regulation of cellular component movement
GO:0051604 protein maturation
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0072376 protein activation cascade
GO:0072378 blood coagulation, fibrin clot formation
GO:2000147 positive regulation of cell motility
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0005543 phospholipid binding
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005788 endoplasmic reticulum lumen
GO:0005796 Golgi lumen
GO:0009897 external side of plasma membrane
GO:0031233 intrinsic component of external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-140875: Common Pathway of Fibrin Clot Formation
R-HSA-140834: Extrinsic Pathway of Fibrin Clot Formation
R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade)
R-HSA-163841: Gamma carboxylation, hypusine formation and arylsulfatase activation
R-HSA-159740: Gamma-carboxylation of protein precursors
R-HSA-159854: Gamma-carboxylation, transport, and amino-terminal cleavage of proteins
R-HSA-109582: Hemostasis
R-HSA-140837: Intrinsic Pathway of Fibrin Clot Formation
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-159782: Removal of aminoterminal propeptides from gamma-carboxylated proteins
R-HSA-159763: Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between F10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of F10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of F10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0310.943
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5270.477
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3450.553
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3770.719
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2360.443
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.4250.23
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0610.916
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8380.312
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.2450.178
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1120.939
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0960.551
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5250.0173
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of F10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277306.8-6.80.32
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of F10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of F10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by F10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of F10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of F10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between F10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolF10
Namecoagulation factor X
Aliases FXA; Stuart-Prower factor; factor Xa; prothrombinase; Stuart factor
Chromosomal Location13q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting F10 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting F10.
ID Name Drug Type Targets #Targets
DB00025Antihemophilic factor, human recombinantBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11
DB00036Coagulation factor VIIa Recombinant HumanBiotechF10, F3, F7, GGCX, HPN, TFPI6
DB00100Coagulation Factor IX (Recombinant)BiotechF10, F11, F2, F7, F8, GGCX, LRP17
DB00170MenadioneSmall MoleculeBGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC ......13
DB00569Fondaparinux sodiumSmall MoleculeF10, SERPINC12
DB01109HeparinSmall MoleculeF10, FGF1, FGF19, FGF2, FGF4, FGFR1, FGFR2, FGFR4, HGF, PF4, SELP, ......12
DB01225EnoxaparinSmall MoleculeF10, SERPINC12
DB03847Gamma-Carboxy-Glutamic AcidSmall MoleculeBGLAP, F10, F23
DB046734-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINESmall MoleculeF101
DB05362SSR-126517ESmall MoleculeF101
DB05713LY-517717Small MoleculeF101
DB06228RivaroxabanSmall MoleculeF101
DB06245LanoteplaseBiotechANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......17
DB06406IdraparinuxSmall MoleculeF101
DB06605ApixabanSmall MoleculeF101
DB06635OtamixabanSmall MoleculeF101
DB06920EribaxabanSmall MoleculeF101
DB07211(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDESmall MoleculeF10, F22
DB07261THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDESmall MoleculeF101
DB072772-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDESmall MoleculeF10, F22
DB072782-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDESmall MoleculeF10, F22
DB076052-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDESmall MoleculeF101
DB07629N-((1R,2S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDESmall MoleculeF101
DB07630N-((1R,2R)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDESmall MoleculeF101
DB07800N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDESmall MoleculeF101
DB078045-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1H-1,2,4-TRIAZOLE-3-SULFONAMIDESmall MoleculeF101
DB078435-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDESmall MoleculeF101
DB078446-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDESmall MoleculeF101
DB078476-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4-MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDESmall MoleculeF101
DB078485-Chloro-N-{(3S)-1-[(2S)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1H-indole-2-sulfonamideSmall MoleculeF101
DB078725-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamideSmall MoleculeF101
DB078755-Chloro-thiophene-2-carboxylic acid ((3S,4S)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amideSmall MoleculeF101
DB07973N-(1-ISOPROPYLPIPERIDIN-4-YL)-1-(3-METHOXYBENZYL)-1H-INDOLE-2-CARBOXAMIDESmall MoleculeF101
DB079741-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDESmall MoleculeF101
DB081435-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDESmall MoleculeF101
DB081735-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDESmall MoleculeF101
DB081745-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL)THIOPHENE-2-CARBOXAMIDESmall MoleculeF101
DB08426THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDESmall MoleculeF101
DB084873-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDESmall MoleculeF101
DB084884-{[(E)-2-(5-CHLOROTHIEN-2-YL)VINYL]SULFONYL}-1-(1H-PYRROLO[3,2-C]PYRIDIN-2-YLMETHYL)PIPERAZIN-2-ONESmall MoleculeF101
DB084954-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDESmall MoleculeF101
DB087454-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONESmall MoleculeF101
DB087461-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-4-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINESmall MoleculeF101
DB09075EdoxabanSmall MoleculeF101
DB09109Turoctocog alfaBiotechF10, F2, F93
DB09258BemiparinSmall MoleculeF10, SERPINC1, SERPIND13
DB09329Antihemophilic Factor (Recombinant), PEGylatedBiotechF10, F9, VWF3
DB09332KappadioneSmall MoleculeF10, F2, F7, F9, GGCX, PROC, PROS17
DB11166Antithrombin AlfaBiotechF10, F22
DB12364BetrixabanSmall MoleculeF101
DB12598NafamostatSmall MoleculeF10, F12, F2, ICAM1, KLK1, PRSS16
DB13149Protein S humanBiotechF10, F5, PROC3
DB13150Coagulation factor VII humanBiotechF10, F3, F93
DB13151Anti-inhibitor coagulant complexBiotechF10, F13A1, F2, F5, F7, F8, FGA, FGB8
DB13152Coagulation Factor IX HumanBiotechF10, F11, F2, F7, F8, GGCX, LRP17
DB13192Antihemophilic factor humanBiotechF10, F92
DB13923EmicizumabBiotechF10, F92
DB13933Nonacog beta pegolBiotechF10, F7, F83
DB13998Lonoctocog alfaBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11
DB13999Moroctocog alfaBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11